Phase III REGION-I Study Shows PEP005 (ingenol Mebutate) Gel 0.05% May Reduce Pre-Cancerous Skin Lesions In Patients With Actinic Keratosis
March 7, 2010 – 3:21 amSpecialty pharmaceutical company LEO Pharma announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105). Results from REGION-I demonstrated treatment with PEP005 Gel once daily for 2 consecutive days (n=117) on non-head locations resulted in significant clearance of AK lesions when compared with the vehicle or placebo (n=118). The study showed a 66…
Related Info :
Tags: 0.05%, Actinic, Actinic Keratosis, American Academy, Annual Meeting, Consecutive Days, Cursor, ingenol, Keratosis, Leo Pharma, Lesions, Mebutate, Patients, PEP005, Pharmaceutical Company, Phase, Phase Iii, Placebo, PreCancerous, Reduce, REGIONI, shows, Skin, Skin Cancer, Skin Lesions, Study
